MRI to monitor treatment efficacy in multiple sclerosis

Journal of Neuroimaging

Volumn 17, Issue SUPPL. 1, 2007, Pages

  Fazekas, Franz ^a   Soelberg Sorensen, Per ^b   Comi, Giancarlo ^c   Filippi, Massimo ^d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Rigshospitalet   (Denmark)

^c Department of Neurology ^*  (Austria)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Biomarker; Clinical practice; Drug trials; MRI; Multiple sclerosis; Treatment response

Indexed keywords

GADOLINIUM;

BRAIN SIZE; CLINICAL EVALUATION; CLINICAL FEATURE; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFORMATION PROCESSING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME VARIABLE; PATHOPHYSIOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SPINAL CORD; STANDARDIZATION;

ATROPHY; BRAIN; CONTRAST MEDIA; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 34147175056     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2007.00138.x     Document Type: Review

References (26)

1. Fazekas F, Barkhof F, Filippi M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999;53:448-456.
2. Polman C, Reingold S, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58:840-846.
3. Paty D, Li D, Group TUMMS, Group TIMSS. Interferon beta-1b is effective in relapsing-remitting multipe sclerosis: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
4. Miller D, Grossman R, Reingold S, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
5. Miller D, Albert P, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16.
6. Kappos L, Moeri D, Radue E, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a metaanalysis. Lancet 1999;353:964-969.
7. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239-245.
8. Li D, Zhao G, Paty D, and the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001;56:1505-1513.
9. Filippi M, Horsfield M, Ader H, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43:499-506.
10. Horsfield M, Barker G, Barkhof F, et al. Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. J Magn Reson Imaging 2003;17:389-397.
11. Filippi M, Gawne-Cain M, Gasperini C, et al. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 1998;50:238-244.
12. Li D, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006;66:1384-1389.
13. Van Walderveen M, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions of T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-1288.
14. Barkhof F, van Waesberghe J, Filippi M, et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001;124:1396-1402.
15. Filippi M, Rovaris M, Rocca M, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001;57:731-733.
16. Miller D, Barkhof F, Frank J, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676-1695.
17. Rudick R, Fisher E, Lee J, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704.
18. Anderson V, Fox N, Miller D. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 2006;23:605-618.
19. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006;108:327-332.
20. Filippi M, Falini A, Arnold D, et al. Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group. J Magn Res Imag 2005;21:669-675.
21. Filippi M, Rocca M, Pagani E, et al. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 2004;61:1409-1412.
22. Inglese M, van Waesberghe J, Rovaris M, et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 2003;60:853-860.
23. Rocca M, Filippi M. Functional MRI to study brain plasticity in clinical neurology. Neurol Sci 2006;27:S24-S26.
24. Goodin D. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 2006;59:597-605.
25. Simon J, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006;27:455-461.
26. Filippi M, Rocca M, Arnold D, et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 2006;13:313-325.